These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 37154625)

  • 1. The differential crosstalk of the skin-gut microbiome axis as a new emerging actor in systemic sclerosis.
    Russo E; Bellando-Randone S; Carboni D; Fioretto BS; Romano E; Baldi S; El Aoufy K; Ramazzotti M; Rosa I; Lepri G; Di Gloria L; Pallecchi M; Bruni C; Melchiorre D; Guiducci S; Manetti M; Bartolucci GL; Matucci-Cerinic M; Amedei A
    Rheumatology (Oxford); 2024 Jan; 63(1):226-234. PubMed ID: 37154625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-sectional study using the University of California, Los Angeles, Scleroderma Clinical Trials Consortium Gastrointestinal Tract Instrument 2.0 (UCLA SCTC GIT 2.0) for gastrointestinal disorders of systemic sclerosis.
    Hisada S; Takeuchi S; Tozawa T; Yamada Y; Ito Y; Kodera M
    J Dermatol; 2024 Jul; ():. PubMed ID: 38963343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of the UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 instrument as a clinical decision aid in the routine clinical care of patients with systemic sclerosis.
    Zampatti N; Garaiman A; Jordan S; Dobrota R; Becker MO; Maurer B; Distler O; Mihai C
    Arthritis Res Ther; 2021 Apr; 23(1):125. PubMed ID: 33888149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Responsiveness of the University of California Los Angeles Scleroderma Clinical Trial Consortium gastrointestinal tract 2.0 (UCLA-SCTC-GIT 2.0)to change in scleroderma patients.
    Suliman YA; Kafaja S; Alemam M; Shaweesh Y; Tavakoli K; Furst DE
    J Scleroderma Relat Disord; 2021 Oct; 6(3):236-241. PubMed ID: 35387210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrative analysis of the gut microbiota and faecal and serum short-chain fatty acids and tryptophan metabolites in patients with cirrhosis and hepatic encephalopathy.
    Wang Q; Chen C; Zuo S; Cao K; Li H
    J Transl Med; 2023 Jun; 21(1):395. PubMed ID: 37330571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reliability and validity of the Korean version of the University of California-Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract instrument in patients with systemic sclerosis.
    Lee TH; Lee JS; Park S; Lee KA; Kim HS
    Korean J Intern Med; 2021 Nov; 36(6):1504-1514. PubMed ID: 33561335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of probiotics on gastrointestinal symptoms and immune parameters in systemic sclerosis: a randomized placebo-controlled trial.
    Marighela TF; Arismendi MI; Marvulle V; Brunialti MKC; Salomão R; Kayser C
    Rheumatology (Oxford); 2019 Nov; 58(11):1985-1990. PubMed ID: 31056685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nailfold videocapillaroscopic patterns and serum autoantibodies in systemic sclerosis.
    Cutolo M; Pizzorni C; Tuccio M; Burroni A; Craviotto C; Basso M; Seriolo B; Sulli A
    Rheumatology (Oxford); 2004 Jun; 43(6):719-26. PubMed ID: 15026581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-resolution manometry compared with the University of California, Los Angeles Scleroderma Clinical Trials Consortium GIT 2.0 in Systemic Sclerosis.
    Abozaid HSM; Imam HMK; Abdelaziz MM; El-Hammady DH; Fathi NA; Furst DE
    Semin Arthritis Rheum; 2017 Dec; 47(3):403-408. PubMed ID: 28624173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended autoantibody panel in Turkish patients with early-stage systemic sclerosis: Coexpressions and their influences on clinical phenotypes.
    Temiz Karadağ D; Komac A; Erez Y; Birlik AM; Sari A; Akdoğan A; Farisogullari B; Kimyon G; Koc E; Arslan D; Karatas A; Koca SS; Kasifoglu N; Yazici A; Hayran KM; Cefle A
    Immun Inflamm Dis; 2023 Dec; 11(12):e1089. PubMed ID: 38134320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gastrointestinal tract involvement in systemic sclerosis: The roles of diet and the microbiome.
    Nguyen AD; Andréasson K; McMahan ZH; Bukiri H; Howlett N; Lagishetty V; Lee SM; Jacobs JP; Volkmann ER
    Semin Arthritis Rheum; 2023 Jun; 60():152185. PubMed ID: 36870237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review and roadmap of the skin, lung and gut microbiota in systemic sclerosis.
    Teaw S; Hinchcliff M; Cheng M
    Rheumatology (Oxford); 2021 Dec; 60(12):5498-5508. PubMed ID: 33734316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gut microbiota profile in systemic sclerosis patients with and without clinical evidence of gastrointestinal involvement.
    Patrone V; Puglisi E; Cardinali M; Schnitzler TS; Svegliati S; Festa A; Gabrielli A; Morelli L
    Sci Rep; 2017 Nov; 7(1):14874. PubMed ID: 29093509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract (GIT) 2.0 Reflux Scale Correlates With Impaired Esophageal Scintigraphy Findings in Systemic Sclerosis.
    Abignano G; Mennillo GA; Lettieri G; Karadag DT; Carriero A; Padula AA; Del Galdo F; Khanna D; D'Angelo S
    J Rheumatol; 2021 Sep; 48(9):1422-1426. PubMed ID: 33452163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dysbiosis of skin microbiome and gut microbiome in melanoma progression.
    Mekadim C; Skalnikova HK; Cizkova J; Cizkova V; Palanova A; Horak V; Mrazek J
    BMC Microbiol; 2022 Feb; 22(1):63. PubMed ID: 35216552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of viremia and CD4 recovery on gut "microbiome-immunity" axis in treatment-naïve HIV-1-infected patients undergoing antiretroviral therapy.
    Russo E; Nannini G; Sterrantino G; Kiros ST; Di Pilato V; Coppi M; Baldi S; Niccolai E; Ricci F; Ramazzotti M; Pallecchi M; Lagi F; Rossolini GM; Bartoloni A; Bartolucci G; Amedei A
    World J Gastroenterol; 2022 Feb; 28(6):635-652. PubMed ID: 35317423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of a low FODMAP diet on gut microbiota in individuals with treated coeliac disease having persistent gastrointestinal symptoms - a randomised controlled trial.
    Herfindal AM; van Megen F; Gilde MKO; Valeur J; Rudi K; Skodje GI; Lundin KEA; Henriksen C; Bøhn SK
    Br J Nutr; 2023 Dec; 130(12):2061-2075. PubMed ID: 37272479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Translation, cross-cultural adaptation, and validation of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument (SCTC GIT) 2.0 into Dutch.
    Meijs J; Pors D; Vliet Vlieland TP; Huizinga TW; Schouffoer AA
    Clin Exp Rheumatol; 2014; 32(6 Suppl 86):S-41-8. PubMed ID: 24984228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.
    Khanna D; Hays RD; Maranian P; Seibold JR; Impens A; Mayes MD; Clements PJ; Getzug T; Fathi N; Bechtel A; Furst DE
    Arthritis Rheum; 2009 Sep; 61(9):1257-63. PubMed ID: 19714600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic sclerosis is associated with specific alterations in gastrointestinal microbiota in two independent cohorts.
    Volkmann ER; Hoffmann-Vold AM; Chang YL; Jacobs JP; Tillisch K; Mayer EA; Clements PJ; Hov JR; Kummen M; Midtvedt Ø; Lagishetty V; Chang L; Labus JS; Molberg Ø; Braun J
    BMJ Open Gastroenterol; 2017; 4(1):e000134. PubMed ID: 28761687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.